This company seems to have been delisted
Reason: Acquired by Pfizer
Last recorded trade on: February 9, 2024
Source: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen
Reason: Acquired by Pfizer
Last recorded trade on: February 9, 2024
Source: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen
Seagen
SGEN
C$310.59
Share price
-0.07%
Change (1 day)
68.47%
Change (1 year)
Categories
Seagen (SGEN) - Total liabilities
Total liabilities on the balance sheet as of September 2023 : C$1.47 Billion
According to Seagen 's latest financial reports the company's total liabilities are C$1.47 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Seagen - Total liabilities on balance sheet (from 2001 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | C$1.18 B | 41.66% |
| 2021-12-31 | C$0.83 B | 27.56% |
| 2020-12-31 | C$0.65 B | 51.9% |
| 2019-12-31 | C$0.43 B | 37.76% |
| 2018-12-31 | C$0.31 B | 24.03% |
| 2017-12-31 | C$0.25 B | -8.24% |
| 2016-12-31 | C$0.27 B | -5.38% |
| 2015-12-31 | C$0.29 B | 0.77% |
| 2014-12-31 | C$0.28 B | 6.62% |
| 2013-12-31 | C$0.27 B | 10.73% |
| 2012-12-31 | C$0.24 B | 16.19% |
| 2011-12-31 | C$0.20 B | 24.69% |
| 2010-12-31 | C$0.16 B | -12.15% |
| 2009-12-31 | C$0.19 B | 45% |
| 2008-12-31 | C$0.13 B | 40.13% |
| 2007-12-31 | C$94.31 M | 756.23% |
| 2006-12-31 | C$11.01 M | -35.02% |
| 2005-12-31 | C$16.95 M | -7.6% |
| 2004-12-31 | C$18.34 M | 98.63% |
| 2003-12-31 | C$9.23 M | 0.25% |
| 2002-12-31 | C$9.21 M | 145.39% |
| 2001-12-31 | C$3.75 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 ImmunoGen
IMGN | C$0.35 B | -75.96% | 🇺🇸 USA |
 Biogen BIIB | C$15.01 B | 919.93% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | C$49.54 M | -96.63% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | C$0.10 B | -92.54% | 🇺🇸 USA |
 Pfizer PFE | C$159.39 B | 10,731.03% | 🇺🇸 USA |
 GlaxoSmithKline GSK | C$82.54 B | 5,509.14% | 🇬🇧 UK |
 AbbVie ABBV | C$182.90 B | 12,328.31% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | C$101.81 B | 6,817.90% | 🇺🇸 USA |